Hyperphosphatemia Treatment Market SWOT Analysis 2023-2030 : Including Top Players - Sanofi, Takeda Pharmaceutical Company, Astellas Pharma

The Hyperphosphatemia Treatment Market Report provides gathered information about the market in an industry or specific sector. With a forecast period from 2023 to 2030, the Hyperphosphatemia Treatment Market report provides an analysis in terms of both quantitative as well as Qualitative information. Various factors, such as product prices, product or service penetration at both national and regional level, country GDP, market dynamics of parent markets and children's markets, end use industries, major players, consumer behaviour, economic, political, social scenarios of countries, many others, are to be taken into account in the report.

Drawing from SNS Insider's research, it's revealed that Hyperphosphatemia, characterized by excessive phosphate levels, can stem from conditions like hypoparathyroidism and chronic kidney disease (CKD), among other factors. Notably, the global landscape witnesses a notable surge in CKD prevalence. For instance, data from the International Society for Nephrology in 2022 suggests that over 10% of the world's population grapples with kidney disease. Furthermore, this affliction disproportionately affects the elderly, alongside individuals battling hypertension and diabetes mellitus.

Get a Free PDF Sample of Report @ https://www.snsinsider.com/sample-request/3451

Market Size and Growth :

Recent findings from SNS Insider shed light on the Hyperphosphatemia Treatment Market, indicating a solid valuation of USD 2.58 billion in 2022. With a strategic outlook, the market is poised for expansion, targeting an ambitious USD 3.84 billion by 2030. Bolstered by a calculated compound annual growth rate (CAGR) of 5.1% forecasted from 2023 to 2030, this trajectory epitomizes a narrative of industry resilience and strategic foresight. Prepare for a professional journey characterized by innovation, opportunity, and sustained growth within the hyperphosphatemia treatment sector.

Major Key Players :

→ Sanofi
→ Takeda Pharmaceutical Company
→ Astellas Pharma
→ Ardelyx
→ Unicycive Therapeutics
→ Keryx Biopharmaceuticals
→ Zeria Pharmaceuticals
→ Vifor Pharma Management
→ Lupin Limited others

Market Growth Factors :

The growth in the hyperphosphatemia treatment market is driven by an increased incidence of chronic disease among patients. Chronic diseases are non-communicable and require long-term care. A vast majority of chronic diseases can be categorized as cardiovascular diseases, chronic kidney disease, chronic respiratory conditions, hyperparathyroidism, diabetes, and cancer. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million deaths, which is 74.0% of those caused by non-communicable diseases (NCDs) or chronic diseases every year globally.

Segmentation Analysis :

The market divided into sevelamer, calcium based phosphate binders, lanthanum carbonate, iron Phosphate binder, nonphosphate degradators and others on the basis of test type. In 2022, the ironphosphate phosphate binders segment accounted for a major share of the hyperphosphatemia treatment market and is expected to show significant compound annual growth over the forecast period. The large sales of products under the brands Auryxia and Velphoro are responsible for its dominance in this segment. In addition, the growth of this segment is also driven by manufacturers' increasing emphasis on protecting their products from generic competition.

The market consists of hospital pharmacies, retailers and online pharmacies according to distribution channels. In 2022, the hospital pharmacies segment accounted for a large market share in hyperphosphatemia treatment worldwide. The dominance of the segment is mainly due to the large number of patients who seek dialysis in hospitals. In addition, there has been a significant increase in the number of dialysis patients in these settings in emerging economies such as India, where the cost of treatment is one of the key factors. This segment is therefore expected to grow on the back of a large number of patients in hospitals.

Key Market Segmentation :

By Product
→ Sevelamer
→ Calcium-Based phosphate Binders
→ Iron-Based phosphate Binders
→ Lanthanum Carbonate
→ Others
→ Non-Phosphate Binders

By Distribution Channel
→ Hospital Pharmacy
→ Retail Pharmacy
→ Online Stores

Key Regional Development :

The hyperphosphatemia treatment market in North America accounted for the largest share and was worth USD 0.53 billion as at 2022. The presence of a large number of patients with chronic kidney disease undergoing dialysis in the region contributes to the high revenue generated by the regional market. According to the statistics published by the National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK) in May 2023, an estimated 808,000 people in the U.S. were living with End-Stage Renal Disease (ESRD), out of which 69% of them were on dialysis. Therefore, in the forecast period demand for hyperphosphatemia treatment is expected to be substantially increased on account of this factor.

During the forecast period, Asia Pacific is expected to experience robust growth. As compared to developed countries, the market in China, India and other emerging countries is characterised by a higher demand for calcium phosphate-based binders. However, the main factors that are expected to increase the demand for hyperphosphatemia treatment in the region over the forecast period are the changing prescribing patterns in these countries and a significantly increased number of patients undergoing dialysis in the Asia Pacific region.

Get full detailed Access to Hyperphosphatemia Treatment Market @ https://www.snsinsider.com/enquiry/3451

Key Takeaway from Hyperphosphatemia Treatment Market Study :

In dialysis patients, controlling phosphate levels is crucial. Phosphate levels are still not effectively controlled even after dialysis technology has been improved. Furthermore, hyperphosphatemia in dialysis patients may be caused by changes in the dialytic removal of phosphates, an unknown absorption of enteric phosphate through diet or vitamin D and binding effectiveness. Therefore, researchers are focused on the development of novel hyperphosphatemia treatments and updates to treatment guidelines with a view to increasing the effectiveness of therapy for hyperphosphatemia in patients undergoing dialysis.

Recent Development Related to Hyperphosphatemia Treatment Market :

→ In October 2022, Vifor, now a subsidiary of CSL, won the patent case against Teva Pharmaceutical Industries Ltd. for its product Velphoro. Consequently, until July 2030 Velphoro will continue to enjoy the protection of its patent against any general competition.

→ In March 2022, In the United States, Lupin launched Sevelamer Hydrochloride tablets for the treatment of hyperphosphatemia in patients with chronic kidney disease. The introduction of this product has increased the company's portfolio in the market.

Buy This Exclusive Report @ https://www.snsinsider.com/checkout/3451

Table of Contents - Major Key Points

1.Introduction
2.Research Methodology
3.Market Dynamics
4.Impact Analysis
4.1COVID-19 Impact Analysis
4.2Impact of Ukraine- Russia war
4.3Impact of ongoing Recession
5.Value Chain Analysis
6.Porter's 5 Forces Model
7.PEST Analysis
8.Hyperphosphatemia Treatment Market Segmentation, by Product
9.Hyperphosphatemia Treatment Market Segmentation, by Distribution Channel
10.Regional Analysis
11.Company Profiles
12.Competitive Landscape
13.Conclusion
Continued….

Get detailed Report with Graphs and TOC @ https://www.snsinsider.com/reports/hyperphosphatemia-treatment-market-3451

Akash Anand - Head of Business Development & Strategy,
Phone: +1-415-230-0044 (US) | +91-7798602273 (IND),
info@snsinsider.com
Website: https://www.snsinsider.com/

SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.
We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.

This release was published on openPR.